ð åèç
å¿
è â Types
- Flu A: H1N1, H3N2 (seasonal), pandemic potential via reassortment
- Flu B: Victoria only (Yamagata extinct post-COVID)
å¿
è â Antigenic Variation
- Drift: point mutations â annual variation
- Shift: reassortment â pandemic (only Flu A)
å¿
è â Clinical
- Fever ⥠39 + headache + myalgia + fatigue + cough
- Abrupt onset, âknocks flatâ
- 5-7d duration
å¿
è â High-Risk Groups
- ⥠65 yr
- < 2 yr
- Pregnant
- Chronic cardiopulmonary/DM/CKD/immunocompromise
- BMI ⥠40
å¿
è â Complications
- Primary viral pneumonia (ARDS)
- Secondary bacterial (S. pneumo, S. aureus PVL+ necrotizing, GAS)
- Myocarditis, MI
- Encephalopathy (IAE pediatric)
- Myositis, rhabdomyolysis
- No aspirin in children (Reyeâs)
å¿
è â Treatment
- Oseltamivir 75 bid à 5d â within 48 hr onset
- Baloxavir single dose alternative
- Hospitalized: start empirical immediately
- Pregnancy: oseltamivir safe + recommended
å¿
è â Vaccines
- Universal ⥠6 mo annual
- 2024-2025 trivalent (Yamagata dropped)
- IIV3, RIV, LAIV (nasal, 2-49 yr), High-dose / Adjuvanted for ⥠65
å¿
è â H5N1 2024
- USA dairy cattle outbreak
- Farmworker mild cases
- First USA death Jan 2025
- Pandemic preparedness alert